Mirati Therapeutics, Inc. won accelerated approval from the US Food and Drug Administration for its KRAS G12C inhibitor Krazati (adagrasib) for second-line or later treatment of patients with non-small cell lung cancer (NSCLC) who have a KRAS G12C mutation, reaching the market about 18 months after Amgen, Inc.’s Lumakras (sotorasib) in the same indication. It remains to be seen whether Krazati’s labeling gives the drug a competitive advantage, but its list price is above current Lumakras pricing.
San Diego-based Mirati priced its first commercial product at $19,750 for a one-month supply, or $237,000 per year before rebates...
